Advertisement

Topics

NeoStem to Present at Two Conferences in Late June

20:00 EDT 3 Jun 2015 | Globe Newswire

NEW YORK, June 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) (to be renamed Caladrius Biosciences, Inc. as of June 8, 2015), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today that the Company's management and experts will present at two conferences in late June.

2015 BIO International Convention

Session 1

Session 2

  • Date and Time: Thursday, June 18, 2015, 10:30 AM ET
  • Venue: Pennsylvania Convention Center, Philadelphia, PA
  • Website: https://mybio2015.zerista.com/event/member/162841
  • Panelist: Dr. Robert O. Dillman, Vice President, Oncology
  • Topic: Leveraging the Immune System to Cure Disease: Emerging Approaches

International Society for Stem Cell Research Annual Meeting

  • Date and Time: Wednesday, June 24, 2015, 8:40 AM WEDT
  • Venue: StockholmsmässanExhibition and Convention Center, Stockholm, Sweden
  • Website: http://www.isscr.org/home/annual-meeting/isscr2015
  • Presenter: Dr. Hans Keirstead, President, Oncology
  • Topic: Development of an Immune Based Therapy for Melanoma

About NeoStem, Inc. (soon to be renamed Caladrius Biosciences, Inc. with ticker to be CLBS)

NeoStem is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. NeoStem is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.

CONTACT: NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

NeoStem Inc. Logo

NEXT ARTICLE

More From BioPortfolio on "NeoStem to Present at Two Conferences in Late June"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...